Wave Life Sciences (WVE) shares were higher premarket Wednesday after the company reported "positive" 48-week data from a phase 2 trial of its WVE-N531 drug candidate in boys with Duchenne muscular dystrophy who are amenable to exon 53 skipping.
The biotechnology company said the boys received 10 milligrams of the exon skipping oligonucleotide every two weeks for each kilogram of their weight, with WVE-N531 meeting all trial goals, including sustained and industry-leading exon skipping, muscle concentrations and dystrophin restoration,
WVE-N531 also demonstrated a 61-day tissue half-life support in monthly dosing. It also continues to be safe and well-tolerated, the company said.
Wave also said it recently met with the US Food and Drug Administration to discuss its interim 24-week data and initial plans for a confirmatory phase 3 trial, with the agency confirming WVE-N531 remains on an accelerated approval pathway using dystrophin expression as a surrogate endpoint.
The company also expects to file a new drug application in 2026 for accelerated approval of WVE-N531 based on FDA feedback and the new 48-week data.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。